Compare Stocks: ATYR, PLX, ALEC, and VYGR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.01 +18.6%	$1.68	$1.09 ▼ $3.40	$225.78M	0.6	811,424 shs	3.45 million shs
ATYR aTyr Pharma	$0.52 -1.1%	$0.51	$0.40 ▼ $6.50	$50.69M	0.54	1.97 million shs	277,502 shs
PLX Protalix BioTherapeutics	$2.44 -1.8%	$2.26	$1.46 ▼ $3.19	$196.19M	0.02	932,728 shs	99,496 shs
VYGR Voyager Therapeutics	$3.24 +2.1%	$3.39	$2.93 ▼ $5.55	$195.46M	1.31	646,922 shs	170,960 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-5.06%	+11.92%	+4.97%	-21.76%	-21.40%
ATYR aTyr Pharma	+3.42%	+7.50%	-2.85%	-0.25%	-90.02%
PLX Protalix BioTherapeutics	+0.81%	+6.90%	+1.64%	+29.84%	+61.04%
VYGR Voyager Therapeutics	-3.06%	+5.67%	-7.85%	-23.61%	+0.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.01 +18.6%	$1.68	$1.09 ▼ $3.40	$225.78M	0.6	811,424 shs	3.45 million shs
ATYR aTyr Pharma	$0.52 -1.1%	$0.51	$0.40 ▼ $6.50	$50.69M	0.54	1.97 million shs	277,502 shs
PLX Protalix BioTherapeutics	$2.44 -1.8%	$2.26	$1.46 ▼ $3.19	$196.19M	0.02	932,728 shs	99,496 shs
VYGR Voyager Therapeutics	$3.24 +2.1%	$3.39	$2.93 ▼ $5.55	$195.46M	1.31	646,922 shs	170,960 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-5.06%	+11.92%	+4.97%	-21.76%	-21.40%
ATYR aTyr Pharma	+3.42%	+7.50%	-2.85%	-0.25%	-90.02%
PLX Protalix BioTherapeutics	+0.81%	+6.90%	+1.64%	+29.84%	+61.04%
VYGR Voyager Therapeutics	-3.06%	+5.67%	-7.85%	-23.61%	+0.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	114.50% Upside
ATYR aTyr Pharma	2.25	Hold	$17.00	3,114.22% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	383.87% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	420.50% Upside

Current Analyst Ratings Breakdown

Latest ATYR, PLX, ALEC, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	VYGR Voyager Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/26/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/22/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/20/2026	ATYR aTyr Pharma	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	8.96	N/A	N/A	$0.28 per share	6.04
ATYR aTyr Pharma	$190K	272.94	N/A	N/A	$0.69 per share	0.77
PLX Protalix BioTherapeutics	$76.38M	2.62	$0.14 per share	17.80	$0.47 per share	5.28
VYGR Voyager Therapeutics	$40.37M	4.74	N/A	N/A	$3.53 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	N/A
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-88.95%	-65.31%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.18	N/A	8.00	N/A	-21.03%	-30.89%	-11.74%	N/A
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-54.82%	-42.53%	N/A

Latest ATYR, PLX, ALEC, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million
5/15/2026	Q1 2026	ATYR aTyr Pharma	-$0.16	-$0.11	+$0.05	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
ATYR aTyr Pharma	N/A	5.78	5.78
PLX Protalix BioTherapeutics	N/A	1.98	1.27
VYGR Voyager Therapeutics	N/A	8.42	8.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
ATYR aTyr Pharma	61.72%
PLX Protalix BioTherapeutics	16.53%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
ATYR aTyr Pharma	5.75%
PLX Protalix BioTherapeutics	6.70%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
ATYR aTyr Pharma	53	98.05 million	92.41 million	Optionable
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable
VYGR Voyager Therapeutics	100	60.42 million	52.75 million	Optionable

ATYR, PLX, ALEC, and VYGR Headlines

Recent News About These Companies

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

August 10 at 8:11 AM | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results

August 6, 2026 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Therapeutics (VYGR) to Announce Earnings on Wednesday

August 4, 2026 | americanbankingnews.com

Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50 Day Moving Average - Here's What Happened

July 23, 2026 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Below 50-Day Moving Average - Should You Sell?

July 15, 2026 | marketbeat.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | markets.businessinsider.com

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | globenewswire.com

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

June 10, 2026 | theglobeandmail.com

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

June 10, 2026 | tipranks.com

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

June 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, PLX, ALEC, and VYGR Company Descriptions

Alector NASDAQ:ALEC

$2.00 +0.32 (+18.64%)

As of 01:21 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

aTyr Pharma NASDAQ:ATYR

$0.52 -0.01 (-1.12%)

As of 01:21 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Protalix BioTherapeutics NYSE:PLX

$2.44 -0.05 (-1.81%)

As of 01:22 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Voyager Therapeutics NASDAQ:VYGR

$3.24 +0.07 (+2.05%)

As of 01:22 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, PLX, ALEC, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, PLX, ALEC, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, PLX, ALEC, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, PLX, ALEC, and VYGR Company Descriptions

Alector NASDAQ:ALEC

aTyr Pharma NASDAQ:ATYR

Protalix BioTherapeutics NYSE:PLX

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, PLX, ALEC, and VYGR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, PLX, ALEC, and VYGR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, PLX, ALEC, and VYGR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, PLX, ALEC, and VYGR Company Descriptions

Alector NASDAQ:ALEC

aTyr Pharma NASDAQ:ATYR

Protalix BioTherapeutics NYSE:PLX

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools